Aditxt, Inc. Share Price

Equities

ADTX

US0070256047

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
2.39 USD -5.53% Intraday chart for Aditxt, Inc. +1.70% -63.95%
Sales 2022 0.93 77.89 Sales 2023 0.65 53.82 Capitalization 8.28M 691M
Net income 2022 -27M -2.25B Net income 2023 -32M -2.67B EV / Sales 2022 59,68,543 x
Net Debt 2022 613K 51.15M Net Debt 2023 18.12M 1.51B EV / Sales 2023 4,09,20,944 x
P/E ratio 2022
-0.08 x
P/E ratio 2023
-0.06 x
Employees 47
Yield 2022 *
-
Yield 2023
-
Free-Float 97.51%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.53%
1 week+1.70%
Current month-29.71%
1 month-29.71%
3 months-38.87%
6 months-66.53%
Current year-63.95%
More quotes
1 week
2.18
Extreme 2.18
2.69
1 month
2.14
Extreme 2.14
5.45
Current year
2.14
Extreme 2.14
6.34
1 year
2.14
Extreme 2.14
68.08
3 years
2.14
Extreme 2.14
7 900.00
5 years
2.14
Extreme 2.14
19 160.00
10 years
2.14
Extreme 2.14
19 160.00
More quotes
Managers TitleAgeSince
Founder 61 28/17/28
Chief Executive Officer 54 28/17/28
Director of Finance/CFO 51 01/20/01
Members of the board TitleAgeSince
Director/Board Member 67 10/20/10
Chief Executive Officer 54 28/17/28
Founder 61 28/17/28
More insiders
Date Price Change Volume
26/24/26 2.39 -5.53% 65,777
25/24/25 2.53 +6.75% 181,004
24/24/24 2.37 +4.41% 28,051
23/24/23 2.27 +2.25% 26,841
22/24/22 2.22 -5.53% 62,239

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
More about the company

Quarterly revenue - Rate of surprise